Beijing Hanmi Pharmaceutical Co., Ltd.

Beijing Hanmi Pharm. Co., Ltd.

Evonik Operations Gmbh

Hanmi Science Co., Ltd.

Innovent Biologics (suzhou) Co., Ltd.

Jiawang Liu

Yaping Yang

Nanmeng Song

Maengsup Kim

Mengxie Jin

Dongge Yang

Hongjuan Zhang

Wenchu Xiao

Robert Franke

Se Chang Kwon

Yang Yang

Matthias Beller

Sung Youb Jung

Ralf Jackstell

Jae Ho Lee

In Young Choi

Kaiwu Dong

Sung Hwan Moon

Helfried Neumann

Young Eun Woo

Lina Zhang

Mi Young Cha

Zhenlei Li

Se Young Lim

Guoqiang Chen

Qingqing Yin

Yao Yan

Maeng Sup Kim

Mingyue Gu

Chunguang Zhan

Chulwoong Chung

Beller Matthias,

Provided are an anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.

Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor

An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.

Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof

Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same

Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.

Anti-PD-L1/anti-CD47 bispecific antibody

Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.

Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof

The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.

Heterodimeric immunoglobulin constructs and preparation methods thereof

Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.

Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.

Antibody specifically binding to PD-1 and functional fragment thereof

An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.

Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody

Propyl-bridged diphosphine compounds, metal complexes of these compounds and the use thereof for alkoxycarbonylation.

Propyl-bridged diphosphine ligands for alkoxycarbonylation

A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.

Method for treating cancer using an interferon alpha conjugate

Growing community of inventors

Beijing, China

Jiawang Liu